Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, ...
Tempus AI (TEM) has moved back into focus after receiving 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI tool for early mitral regurgitation detection. The FDA ...
Tempus AI, Inc. is currently listed on NASDAQ under TEM. One share of TEM stock can currently be purchased for approximately $71.98. Is Tempus AI, Inc. listed on the NASDAQ or NYSE? Tempus AI, Inc. is ...
TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they’ve made some interesting moves ...
A U.K. startup wants to do for utilities what neobanks have been doing for the financial sector for more than a decade: disrupt an age-old industry using technology, streamline it and cut out the ...
A significant technology, Transmission electron microscopy (TEM) has found its way into cell biology since 1940. When compared with light microscopes, TEM can achieve a very high resolution due to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results